"Not So Different": Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab

December 8, 2019

Just last month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.

Just last month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.

An spoke with us prior to the authorization about subcutaneous CT-P13, Celltrion’s plans for the days ahead in terms of bringing the drug to Europe, treatment sequencing, and an ongoing US phase 3 study in inflammatory bowel disease.

Read more about the Committee for Medicinal Products for Human Use’s opinion, the drug’s authorization, and the PANTS study.

Related Content:

Podcasts | Business

x